Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …

Renal cell carcinoma (RCC) is a highly vascularized tumor and prone to distant metastasis.
Sorafenib is the first targeted multikinase inhibitor and first-line chemical drug approved for …

Background Understanding how to sequence targeted therapies for metastatic renal cell
carcinoma (mRCC) is important for maximisation of clinical benefit. Objectives To …

In metastatic renal cell carcinoma (mRCC), many factors influence clinical decisions,
including histology, tumour burden, prognostic factors, comorbidities, and the ability of the …

Background A subset of patients treated with initial anti-vascular endothelial growth factor
(VEGF) therapy exhibit progressive disease (PD) as the best response per RECIST criteria …

Background: This retrospective register study assessed overall survival (OS) and influential
factors on OS in Swedish renal cell carcinoma (RCC) patients. Methods: Using three merged …

Context: Sorafenib, a tyrosine kinase inhibitor, is a common first-line therapy for advanced
differentiated thyroid cancer (DTC). However, responses are not durable and drug toxicity …

The prognosis of patients affected by metastatic renal cell carcinoma (mRCC) has improved
markedly with targeted therapies. Unfortunately, 20–25% of the patients are refractory to …

Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects,
although an indirect inhibitory effect on tumor growth and, more recently, a complex activity …

Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various
receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib …